Lawrence Otto Klein - 16 Mar 2026 Form 4 Insider Report for Oruka Therapeutics, Inc. (ORKA)

Role
Chief Executive Officer, Director
Signature
/s/ Paul Quinlan, as attorney-in-fact for Lawrence Klein
Issuer symbol
ORKA
Transactions as of
16 Mar 2026
Net transactions value
-$71,408
Form type
4
Filing time
17 Mar 2026, 16:10:21 UTC
Previous filing
23 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Klein Lawrence Otto Chief Executive Officer, Director C/O ORUKA THERAPEUTICS, INC., 855 OAK GROVE AVE., SUITE 100, MENLO PARK /s/ Paul Quinlan, as attorney-in-fact for Lawrence Klein 17 Mar 2026 0001762583

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ORKA Common Stock Sale $71,408 -1,729 -0.19% $41.30 927,309 16 Mar 2026 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units.